ScholarLens Back to search
2006•Expert Review of NeurotherapeuticsOpen access

The curtain is drawn for both natalizumab and fingolimod (FTY720): a new era of multiple sclerosis therapy has arrived

Robert Weissert

Open full text 4 citations

Abstract

A new era of treatment in multiple sclerosis (MS) has arrived. Novel drugs target the migration of T lymphocytes to the CNS in MS. With the introduction of natalizumab (TysabriTM, Biogen Idec), a n...

Open-access reader

About this research paper

What this paper is about

A new era of treatment in multiple sclerosis (MS) has arrived. Novel drugs target the migration of T lymphocytes to the CNS in MS. With the introduction of natalizumab (TysabriTM, Biogen Idec), a n...

Why it matters

OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

A new era of treatment in multiple sclerosis (MS) has arrived. Novel drugs target the migration of T lymphocytes to the CNS in MS. With the introduction of natalizumab (TysabriTM, Biogen Idec), a n...

Key concepts: Natalizumab, Fingolimod, Multiple sclerosis, Medicine, Progressive multifocal leukoencephalopathy, Immunology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
The curtain is drawn for both natalizumab and fingolimod (FTY720): a new era of multiple sclerosis therapy has arrived — Research Paper | ScholarLens